Sin categoría – Página 17 – SEIOMM, Sociedad Española de Investigación Ósea

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Bone. 2018 Oct 22;120:137-140. doi: 10.1016/j.bone.2018.10.015 Miller PD(1), Hattersley G(2), Lau E(3), Fitzpatrick LA(4), Harris AG(5), Williams GC(4), Hu MY(4), Riis BJ(6), Russo L(7), Christiansen C(6). DOI: 10.1016/j.bone.2018.10.015 -PMID: 30359763

High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease.

Nephrol Dial Transplant. 2018 Sep 5. Carrillo-López N, Panizo S, Alonso-Montes C, Martínez-Arias L, Avello N, Sosa P, Dusso AS, Cannata-Andía JB, Naves-Díaz M.

Do sarcopenia and/or osteoporosis increase the risk of frailty? A 4-year observation of the second and third ROAD study surveys.

Osteoporos Int. 2018 Jun 21. doi: 10.1007/s00198-018-4596-4. DOI: 10.1007/s00198-018-4596-4 -PMID: 29931626 Yoshimura N(1), Muraki S(2), Oka H(3), Iidaka T(2), Kodama R(4), Horii C(4), Kawaguchi H(5), Nakamura K(6), Akune T(6), Tanaka S(4). https://www.ncbi.nlm.nih.gov/pubmed/29931626

Administration of teriparatide for four years cyclically compared to two years daily in treatment Naïve and alendronate treated women.

Bone. 2018 Oct 21;120:246-253. doi: 10.1016/j.bone.2018.10.020. Cosman F(1), Nieves JW(2), Roimisher C(3), Neubort S(3), McMahon DJ(3), Dempster DW(4), Lindsay R(5). DOI: 10.1016/j.bone.2018.10.020 -PMID: 30355512

High risk and probability of progression to osteoporosis at 10 years in HIV-infected individuals: the role of PIs.

J Antimicrob Chemother. 2018 Sep 1;73(9):2452-2459. Negredo E, Langohr K, Bonjoch A, Pérez-Alvárez N, Estany C, Puig J, Rosales J, Echeverría P, Clotet B, Gómez G.

Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement.

JAMA. 2018 Jun 26;319(24):2521-2531. doi: 10.1001/jama.2018.7498. DOI: 10.1001/jama.2018.7498 -PMID: 29946735 [Indexed for MEDLINE] US Preventive Services Task Force, Curry SJ(1), Krist AH(2)(3), Owens DK(4)(5), Barry MJ(6), Caughey AB(7), Davidson KW(8), Doubeni CA(9), Epling JW Jr(10), … Leer más

Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment.

Bone. 2018 Oct 4;120:44-49. doi: 10.1016/j.bone.2018.10.001. Tsourdi E(1), Makras P(2), Rachner TD(1), Polyzos S(3), Rauner M(1), Mandanas S(4), Hofbauer LC(5), Anastasilakis AD(6). DOI: 10.1016/j.bone.2018.10.001 -PMID: 30292818

Linking of psoriasis with osteopenia and osteoporosis: A cross-sectional study.

Indian J Dermatol Venereol Leprol. 2018 Sep 17. Martinez-Lopez A, Blasco-Morente G, Giron-Prieto MS, Arrabal-Polo MA, Luque-Valenzuela M, Luna-Del Castillo JD, Tercedor-Sanchez J, Arias-Santiago S.

Screening to Prevent Osteoporotic Fractures: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

JAMA. 2018 Jun 26;319(24):2532-2551. doi: 10.1001/jama.2018.6537. DOI: 10.1001/jama.2018.6537 -PMID: 29946734 [Indexed for MEDLINE] Viswanathan M(1)(2), Reddy S(1)(2), Berkman N(1)(2), Cullen K(1)(2), Middleton JC(2)(3), Nicholson WK(4), Kahwati LC(1)(2). https://www.ncbi.nlm.nih.gov/pubmed/29946734

Alterations in non-type I collagen biomarkers in osteogenesis imperfecta.

Bone. 2018 Oct 2;120:70-74. doi: 10.1016/j.bone.2018.09.024 Nicol L(1), Morar P(2), Wang Y(3), Henriksen K(4), Sun S(4), Karsdal M(4), Smith R(5), Nagamani SCS(6), Shapiro J(7), Lee B(6), Orwoll E(8). DOI: 10.1016/j.bone.2018.09.024 -PMID: 30290234